Zogenix (ZGNX) just took a painful one-two punch on the market today, causing shares to fall 15%. First, the company reported Q4 earnings, which missed estimates; but that wasn't the real story with the company today. Much more painful to the stock was the continued lobbying against the company's freshly approved painkiller Zohydro. Despite an 11-2 advisory committee vote against approving the drug due to concerns that it had a high potential for abuse, the FDA still decided to approve the extremely effective drug.
In this video, Motley Fool health-care analyst David Williamson discusses the vocal opponents of the drug, and highlights the company's biggest threat: that the FDA would reconsider, and reverse its decision.
